PDS Biotechnology stock analysis
PDS Biotechnology (EU6) Stock Price & Analysis
EU6 Stock Chart & Stats
- Day’s Range
- EUR 0.76 - EUR 0.86
- 52-Week Range
- EUR 0.17 - EUR 1.59
- Previous Close
- EUR 0.76
- Volume
- N/A
- Average Volume (3M)
- 1,226
- Market Cap
- EUR 75.05M
- Enterprise Value
- EUR 38.79M
- Total Cash (Recent Filing)
- EUR 15.25B
- Total Debt (Recent Filing)
- EUR 33.52M
- Price to Earnings (P/E)
- ―
- Beta
- 0.40
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- -0.05
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline Progress
Encouraging Phase 2 outcomes for PDS0301 in difficult-to-treat metastatic colorectal cancer provide clinical validation for the lead program. The planned registrational Phase 3 path could improve partnering prospects and create a durable value driver if efficacy is confirmed.
PDS0101 Efficacy And Partner Interest
PDS0101 combines differentiated clinical results with identifiable external interest from NantWorks. A potential licensing partnership could help fund Phase 3 development, reduce the company’s burden of advancing the program alone, and validate the platform’s commercial relevance.
Debt Retirement And Strategic Funding
Retiring the Yorkville obligation simplifies near-term liabilities, while the PIPE provides capital for working needs and clinical development. This financing and strategic relationship improve operational continuity and support advancement of PDS0301 toward later-stage trials.
Bears Say
Pre-Revenue Losses
PDS Biotechnology has not yet demonstrated a commercial revenue base and continues to report substantial losses. Until a candidate is approved or partnered economics become meaningful, the business lacks recurring operating income and remains dependent on successful clinical and regulatory execution.
Persistent Cash Burn
Ongoing negative operating and free cash flow shows that the company is not self-funding its research and development activities. Continued dependence on financing leaves execution tied to capital availability and can constrain the pace of pipeline advancement over coming quarters.
Financing Flexibility Constraints
Tighter lender protections reduce management’s discretion over newly raised capital and can limit flexibility in allocating funds among debt repayment, operations, and clinical programs. This raises the importance of future financing structure and milestone timing for sustained development.
PDS Biotechnology News
EU6 FAQ
What was PDS Biotechnology’s price range in the past 12 months?
What is PDS Biotechnology’s market cap?
When is PDS Biotechnology’s upcoming earnings report date?
How were PDS Biotechnology’s earnings last quarter?
Is PDS Biotechnology overvalued?
Does PDS Biotechnology pay dividends?
What is PDS Biotechnology’s EPS estimate?
How many shares outstanding does PDS Biotechnology have?
What happened to PDS Biotechnology’s price movement after its last earnings report?
Which hedge fund is a major shareholder of PDS Biotechnology?
What is the TipRanks Smart Score and how is it calculated?
PDS Biotechnology Stock Smart Score
Company Description
PDS Biotechnology
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Frank K. Bedu-Addo
- Employees
- 21
- Website
- www.pdsbiotech.com
- Address
- 303A College Road East, Princeton, NJ, 08540, US
PDS Biotechnology (EU6) Earnings & Revenues
EU6 Earnings Call
Earnings Call SentimentPositive
The call conveyed meaningful clinical and intellectual property progress: a strategic protocol amendment for VERSATILE-003 that reduces patient count (~28.6%) and time to an interim readout, peer-reviewed and encouraging clinical data for PDS01ADC, strengthened IP extending PDS0101 protection into the 2040s, and established manufacturing processes. Financially, operating expenses and net loss improved year-over-year. Key risks include a relatively modest cash balance ($21.7M), continued unprofitability with rising interest expense, the need for OS data for full approval and additional confirmatory trials, and competition in the HPV16 head and neck space. On balance, the operational and clinical positives outweigh the near-term financial and development risks.
View all DE:EU6 earnings summariesEU6 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 2 | 13 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 2 | 0 | 10 |











